CN107236100A - 一种pH刺激响应性的线形二嵌段聚合前药的制备方法 - Google Patents
一种pH刺激响应性的线形二嵌段聚合前药的制备方法 Download PDFInfo
- Publication number
- CN107236100A CN107236100A CN201710477273.9A CN201710477273A CN107236100A CN 107236100 A CN107236100 A CN 107236100A CN 201710477273 A CN201710477273 A CN 201710477273A CN 107236100 A CN107236100 A CN 107236100A
- Authority
- CN
- China
- Prior art keywords
- oegma
- prodrug
- preparation
- mgma
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940002612 prodrug Drugs 0.000 title claims abstract description 55
- 239000000651 prodrug Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 230000004936 stimulating effect Effects 0.000 title claims abstract description 25
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 6
- 230000008685 targeting Effects 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 90
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 87
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 74
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 72
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 48
- 238000006243 chemical reaction Methods 0.000 claims description 33
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 24
- 229910052786 argon Inorganic materials 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 21
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- 239000007789 gas Substances 0.000 claims description 18
- 239000000693 micelle Substances 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000011724 folic acid Substances 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000178 monomer Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- VHRYZQNGTZXDNX-UHFFFAOYSA-N methacryloyl chloride Chemical compound CC(=C)C(Cl)=O VHRYZQNGTZXDNX-UHFFFAOYSA-N 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 7
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims description 6
- -1 glycine ethyl ester Methacrylamide Chemical compound 0.000 claims description 6
- JYVNDCLJHKQUHE-UHFFFAOYSA-N hydroxymethyl acetate Chemical compound CC(=O)OCO JYVNDCLJHKQUHE-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 4
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 claims description 4
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 3
- 241001076960 Argon Species 0.000 claims description 3
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 3
- 229940009456 adriamycin Drugs 0.000 claims description 3
- 235000013876 argon Nutrition 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- CCMKPCBRNXKTKV-UHFFFAOYSA-N 1-hydroxy-5-sulfanylidenepyrrolidin-2-one Chemical class ON1C(=O)CCC1=S CCMKPCBRNXKTKV-UHFFFAOYSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920000359 diblock copolymer Polymers 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229960001866 silicon dioxide Drugs 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 16
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- 201000011510 cancer Diseases 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000005336 cracking Methods 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 125000003929 folic acid group Chemical group 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000012546 transfer Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 8
- 238000010586 diagram Methods 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 150000004880 oxines Chemical class 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
- C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
- C08F220/281—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing only one oxygen, e.g. furfuryl (meth)acrylate or 2-methoxyethyl (meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
- C08F220/283—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing one or more carboxylic moiety in the chain, e.g. acetoacetoxyethyl(meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2438/00—Living radical polymerisation
- C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2353/00—Characterised by the use of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives of such polymers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种pH刺激响应性的线形二嵌段聚合前药的制备方法及其体外活性,其关键在于,以可逆加成裂解链转移(RAFT)聚合反应为主,通过改变亲水嵌段与疏水嵌段比例合成不同的聚合前药,进一步用叶酸部分修饰合成pH刺激响应性和靶向性兼具的药物递送体系,实验表明该体系药载量高、水溶性好、毒副作用小,有效地提高了药物的利用率,具有精准、高效治疗癌症的潜能。
Description
技术领域
本发明涉及抗肿瘤药物领域,具体涉及一种pH刺激响应性的线形二嵌段聚合前药的制备方法及其体外活性。
背景技术
癌症是威胁人类健康的主要疾病之一,其发病率与死亡率仅次于心血管疾病,如何高效的治疗癌症已备受关注。抗肿瘤药物被广泛用于治疗癌症,它能够通过调控DNA的复制、转录及翻译有效地抑制肿瘤的增殖并促进癌细胞的凋亡,常用的有甲氨喋呤、吡喃阿霉素、盐酸阿霉素以及从天然产物中提取的喜树碱、紫杉醇等,但是这些化学药物在杀死癌细胞的同时损伤了正常细胞和组织,出现呕吐、高热、脱发、免疫力下降等症状,引起这一系列问题的主要原因是抗肿瘤药物的水溶性差,选择性差从而不能在病变部位有效发挥药效,导致它们的应用在临床上受到限制。
采用物理包埋或者化学键合的方式将抗肿瘤药物与纳米载体结合形成胶束既可以大幅度降低药物的毒副作用,又可以实现药物在病变部位的控制释放。研究表明通过靶向试剂对药物载体的修饰,可以提高药物在肿瘤部位的分布使药物充分发挥作用。CN201610987991.6公开了一种pH-氧化还原双响应性的靶向纳米给药载体(肿瘤靶向配体-聚乙二醇-二硫键-聚酰胺-胺-组氨酸),其中组氨酸的修饰增加了载体的酸敏感性,使聚酰胺-胺的质子海绵效应增强,促进药物溶酶体中快速释放。CN201611196325.7公开了一种pH响应胰岛素缓释的三嵌段聚合物(聚乙二醇单甲醚-聚己内酯-聚碱聚甲基丙烯酸-N,N-二乙氨基乙酯),该纳米颗粒能够根据不同pH值进行药物的精准投递,同时能够达到缓释的效果。
由于到达病变部位的药物浓度仍低于治疗所需剂量,因此,构建药载量高、刺激响应性的靶向性药物载体具有重要的意义。
发明内容
本发明的目的之一是一种pH刺激响应性线形聚合前药的制备方法,该方法操作简单,产率高。目的之二是使用所述制备方法制备的聚合物前药具有药载量高、稳定性好、毒副作用小、pH刺激响应性、叶酸靶向性等优点。为实现上述目的,采用以下技术方案:
1)一种pH刺激响应性的线形二嵌段聚合前药的制备方法,包含以下步骤:
(1)亲水单体P(OEGMA)m的制备,其反应式如下所示,包含以下步骤:在氩气(Ar,2-10Pa)条件下,以CPPA-NHS为RAFT反应的大分子引发剂,与乙二醇甲基丙烯酸酯(OEGMA)一并溶于1,4-二氧六环(Dio)中,加入偶氮异丁二腈(AIBN)后,冷冻-解冻循环三次,在70℃下避光反应24h,用液氮冷冻以终止反应,解冻,加3~5mL甲醇稀释,用截留分子量(MWCO)为3500Da的透析袋在甲醇中透析24h,浓缩后得到亲水单体P(OEGMA)m,其中m表示OEGMA的聚合度聚合度(DP),它的范围为5~120;
(2)两亲性单体P(OEGMA)m-b-P(MGMA)n的制备,包含以下步骤:
a)MGMA的制备,其反应式如下所示,包含以下步骤:在冰浴(温度≤0℃)和氩气(Ar,2-10Pa)条件下,羟基乙酸甲酯(MG)溶于含三乙胺(TEA)的二氯甲烷(DCM)溶液中并搅拌0.5h,然后将甲基丙烯酰氯(MA)溶于二氯甲烷(DCM)所形成的混合液缓慢加入,0.5h后置于室温下避光反应12h,过滤除杂,用旋转蒸发仪浓缩溶剂,进一步以乙酸乙酯、正己烷为洗脱剂过硅胶柱除去二取代产物,用旋转蒸发仪浓缩所收集溶液即得纯的甘氨酸乙酯甲基丙烯酰胺(MGMA);
b)P(OEGMA)m-b-P(MGMA)n的制备,其反应式如下所示,包含以下步骤:在氩气(Ar,2-10Pa)条件下,将步骤(1)制备的P(OEGMA)m 作为RAFT反应的大分子引发剂,与步骤(2)a)制备的MGMA一起溶于Dio中,加入AIBN后,冷冻-解冻循环三次,在70℃下避光反应24h,用液氮冷冻以终止反应,解冻,加3~5mL甲醇稀释,用MWCO为3500Da的透析袋在甲醇中透析24h,浓缩后得到两亲性二嵌段聚合物P(OEGMA)m-b-P(MGMA)n,其中n表示MGMA的聚合度(DP),n的范围为10~120;
(3)聚合前药P(OEGMA)m-b-PDOX的制备,其反应式如下所示,包含以下步骤:常温(25℃)通氩 (Ar,2-10Pa)条件下,将步骤(2)制备的二嵌段聚合单体P(OEGMA)m-b-P(MGMA)n与单水合肼(N2H4·H2O)溶于N,N-二甲基甲酰胺(DMF)与甲醇形成的混合液中,避光反应12h,用MWCO为3500Da的透析袋在水中透析24h后冷冻干燥48h得到含酰肼的两亲物P(OEGMA)m-b-hydrazide;将该物质与盐酸阿霉素(DOX.HCl,其结构如下所示),在氩气 (Ar,2-10Pa)条件下溶于含等体积甲醇与DMF的混合液中,加入1滴三氟乙酸(TFA)后避光室温(25℃)反应48h,用MWCO为3500Da的透析袋在甲醇中透析,用旋转蒸发仪浓缩后即得到聚合前药P(OEGMA)m-b-PDOX(简称为OM@DOX);
(4)pH刺激响应性聚合前药OM@DOX纳米胶束的制备,包含以下步骤:取 5 mg步骤(3)制备的聚合前药OM@DOX,溶于含TEA 的DMF混合液中,搅拌0.5 h后,缓慢滴加至二次水中并搅拌0.5 h,用MWCO为3500Da的透析袋在水中透析24 h除去有机溶剂,即得到纳米胶束水溶液。
进一步的,步骤(1)中AIBN、CPPA-NHS和OEGMA的摩尔浓度比为1:(2.4~6.7) :(8~24)。
进一步的,所述步骤(2)a)中TEA与DCM的体积比范围为1:(2~4.5);所述步骤(2)a)中MG和MA的摩尔浓度范围比为1:(1.7~2.3) ;所述步骤(2)a)中乙酸乙酯和正己烷的体积比为1:(3.62~4.8); 所述步骤(2)b)中P(OEGMA)m 和MGMA摩尔浓度比为1:(10~80)。
进一步的,所述步骤(3)中 P(OEGMA)m-b-P(MGMA)n、P(OEGMA)m-b-hydrazide和DOX·HCl的摩尔浓度比为1:(1.2~3.6):(1.4~5.1);所述步骤(3)中N2H4·H2O、甲醇、DMF和TFA的体积比为1:(6~10):(2~7):(0.1~0.4)。
进一步的,步骤(4)的聚合前药中阿霉素的浓度范围为0.01mg·L-1~0.05 mg·L-1; 所述步骤(4)中DMF和水的体积比范围为1:(6~500); 所述步骤(4)中透析后所得的纳米胶束粒径范围为10~1000nm。
2)一种pH刺激响应性的线形二嵌段聚合前药的制备方法,该聚合前药还具有靶向性,包含以下步骤:
(I)FA-NH2的制备,其反应式如下所示,包含以下步骤:在冰浴(温度≤0℃)和氩气(Ar,2-10Pa)条件下,将叶酸(FA)溶于无水的DMF中,加入催化剂1-(3-二甲氨基丙基)-3-乙基碳二亚胺 (EDC)和N-羟基硫代琥珀酰亚胺(NHS),搅拌0.5h后,加入N-叔丁氧羰基-1,6-己二胺(NH2-BOC)溶于含TEA的DMF的混合液,在室温下(25℃)反应24h,缓慢滴加至不断搅拌的二次水中,过滤,真空干燥后得到氨基被叔丁氧羰基保护的FA-NH-BOC,加入DCM和TFA溶剂并搅拌0.5h,浓缩,加入DCM及TEA,避光室温(25℃)搅拌24h,转速设为5000r/min 离心3min,用DCM洗两次,真空干燥后得到FA-NH2;
(II)FA-P(OEGMA)m-b-P(MGMA)n的制备,其反应式如下所示,包含以下步骤:在室温(25℃)通氩(Ar,2-10Pa)条件下将步骤(2)制备的二嵌段聚合物P(OEGMA)m-b-P(MGMA)n与步骤(I)制备的FA-NH2溶于含TEA的无水二甲亚砜(DMSO)溶液中,避光反应48 h后,缓慢滴加至乙醚中沉淀,真空干燥得到接叶酸的两亲性聚合物FA-P(OEGMA)m-b-P(MGMA)n;
(III)聚合前药FA-P(OEGMA)m-b-PDOX的制备,其反应式如下所示,包含以下步骤:常温(25℃)通氩 (Ar,2-10Pa)条件下,将步骤(II)制备的二嵌段共聚物FA-P(OEGMA)m-b-P(MGMA)n与单水合肼(N2H4·H2O)溶于N,N-二甲基甲酰胺(DMF)与甲醇形成的混合液中,避光反应12h,用MWCO为3500Da的透析袋在水中透析24h后冷冻干燥48h得到含酰肼的两亲物FA-P(OEGMA)m-b-hydrazide。将该物质与DOX·HCl在氩气 (Ar,2-10Pa)条件下溶于含等体积甲醇与DMF的混合液中,加入1滴三氟乙酸(TFA)后避光室温(25℃)反应48h,用MWCO为3500Da的透析袋在甲醇中透析,用旋转蒸发仪浓缩后即得到聚合前药FA-P(OEGMA)m-b-PDOX,记为FA-OM@DOX;
(IV)一种pH刺激响应性聚合前药FA-OM@DOX纳米胶束的制备,包含以下步骤:取 5mg步骤(IV)制备的聚合前药FA-OM@DOX,溶于含TEA 的DMF混合液中,搅拌0.5h后,缓慢滴加至二次水中并搅拌0.5h,用MWCO为3500Da的透析袋在水中透析24h除去有机溶剂,即得到纳米胶束水溶液。
进一步的,所述步骤 (I) 中FA、EDC、NHS、NH2-BOC和TEA的摩尔浓度比范围为1:(1.01~1.2):(1.04~1.3):(1.8~2.4) (1.4~2.2);所述步骤 (I) 中DCM、TFA和TEA的体积比范围为1:(0.92~1.08):(1.8~2.4);
进一步的,所述步骤 (II) 中P(OEGMA)m-b-P(MGMA)n、FA-NH2和TEA的摩尔浓度比范围为1:(1.01~1.2) :(1.01~1.2);
进一步的,所述步骤(III) 中FA-P(OEGMA)m-b-P(MGMA)n、 FA-P(OEGMA)m-b-hydrazide和DOX·HCl的摩尔浓度比范围为1:(1.2~3.6):(1.4~5.1);所述步骤(III)中N2H4·H2O、甲醇、DMF和TFA的体积比范围为1:(6~10):(2~7):(0.1~0.4)。
进一步的,步骤(IV)的聚合前药中阿霉素的浓度范围为0.01mg·L-1~0.05 mg·L-1; 所述步骤(IV)中DMF和水的体积比范围为1:(6~500); 所述步骤(IV)中透析后所得的纳米胶束粒径范围为10~1000nm。
主要优点:
针对聚合前药递送体系现存的问题,本项目提出一类pH刺激响应性的线形二嵌段聚合前药递送体系,该体系有效的提高了药物上载量及药物释放量,降低了对正常细胞的毒副作用,最重要的是,该体系可以实现药物的靶向递送并选择性释放,从而实现癌症的精准治疗。
附图说明
为了更加清楚的展现本发明的目的及其技术方案,本发明提供如下附图。
图1为本发明实施例1中的聚合前药OM@DOX和实施例2中的聚合前药FA-OM@DOX的制备流程示意图。
图2为本发明实施例1中的P(OEGMA)m与P(OEGMA)m-b-P(MGMA)n的核磁示意图。
图3为本发明实施例2中的FA-P(OEGMA)m-b-P(MGMA)n与FA-P(OEGMA)m -b-PDOX的核磁示意图。
图4为本发明实施例 1中的聚合前药OM@DOX纳米胶束的DLS和TEM示意图。
图5为本发明实施例1中的聚合前药OM@DOX纳米胶束的释放示意图。
图6为本发明实施例1中的聚合前药OM@DOX纳米胶束和实施例2中的聚合前药FA-OM@DOX纳米胶束的毒性示意图。
具体实施方式
下面将结合附图,对本发明的实施例进行详细的描述。
实施例1 制备pH刺激响应性的聚合前药
1.制备P(OEGMA)m :在氩气(Ar,2-10Pa)条件下,以CPPA-NHS为RAFT反应的大分子引发剂,与乙二醇甲基丙烯酸酯(OEGMA)一并溶于1,4-二氧六环(Dio)中,加入偶氮异丁二腈(AIBN)后,冷冻-解冻循环三次,在70℃下避光反应24h,用液氮冷冻以终止反应,解冻,加3~5mL甲醇稀释,用截留分子量(MWCO)为3500Da的透析袋在甲醇中透析24h,浓缩后以氘代-二甲亚砜为溶剂(DMSO-d6)测氢谱结果如图2(A)所示,1(3.24 ppm) 和2(3.60 ppm)分别为OEGMA上甲氧基和亚甲基氢的信号峰,表明亲水单体P(OEGMA)m成功合成;
2.制备P(OEGMA)m-b-P(MGMA)n:
a)MGMA的制备:在冰浴(温度≤0℃)和氩气(Ar,2-10Pa)条件下,羟基乙酸甲酯(MG)溶于含三乙胺(TEA)的二氯甲烷(DCM)溶液中并搅拌0.5h,然后将甲基丙烯酰氯(MA)溶于二氯甲烷(DCM)所形成的混合液缓慢加入,0.5h后置于室温下避光反应12h,过滤后浓缩即得纯的MGMA;
b)P(OEGMA)m-b-P(MGMA)n的制备:在氩气(Ar,2-10Pa)条件下, P(OEGMA)m 与MGMA一并溶于Dio中,加入AIBN后,冷冻-解冻循环三次,在70℃下避光反应24h,用液氮冷冻以终止反应,解冻,透析24h,浓缩纯化;以氘代氯仿(CDCl3)为溶剂所测的氢谱结果如图2(B)所示,4(3.73 ppm) 与 5(4.55 ppm)分别为MGMA上甲氧基和亚甲基上氢的信号峰,表明两亲性单体P(OEGMA)m-b-P(MGMA)n成功合成;
3.制备P(OEGMA)m-b-PDOX:常温(25℃)通氩 (Ar,2-10Pa)条件下,P(OEGMA)m-b-P(MGMA)n与单水N2H4·H2O溶于DMF与甲醇形成的混合液中,避光反应12h,透析24h后冷冻干燥48h得到含酰肼的两亲物;将该物质与DOX·HCl在氩气 (Ar,2-10Pa)条件下溶于含等体积甲醇与DMF的混合液中,加入1滴三氟乙酸(TFA)后避光室温(25℃)反应48h,透析后浓缩后即得到聚合前药P(OEGMA)m -b-PDOX(OM@DOX);
4.制备聚合前药OM@DOX纳米胶束: 5mg聚合前药OM@DOX溶于含TEA 的DMF混合液中,搅拌0.5h后,缓慢滴加至二次水中并搅拌0.5h,在水中透析24h除去有机溶剂,即得到纳米胶束水溶液;如图4所示,OM@DOX纳米胶束为球状,多分散指数(PDI)比较小,粒径介于1~100之间,表明所制胶束尺寸均匀易进入细胞;体外释放如图5所示,96h 时OM@DOX纳米胶束在pH=5.0的媒介中释放百分比为90.0%,而在pH=7.4的媒介中为11.4%,表明该体系在酸性条件下趋于完全释放,具有pH刺激响应性;体外毒性如图6所示,OM@DOX胶束作用72h 后,图6A)中宫颈癌细胞(Hela)存活率为16.2%,从图6(B)中可以看出对正常细胞的(L929)毒副作用较小。
实施例2 制备pH刺激响应性的聚合前药,该聚合前药还具有靶向性
(I)FA-NH2的制备:在冰浴(温度≤0℃)和氩气(Ar,2-10Pa)条件下,将叶酸(FA)溶于无水的DMF中,加入催化剂EDC和NHS,搅拌0.5h后,加入NH2-BOC溶于含TEA的DMF形成的混合液,在室温下(25℃)反应24h,缓慢滴加至不断搅拌的二次水中,过滤,真空干燥后得到FA-NH-BOC。加入DCM和TFA溶剂并搅拌0.5h,浓缩,加入DCM及TEA,避光室温(25℃)搅拌24h,转速设为5000r/min 离心3min,用DCM洗两次,真空干燥后得到FA-NH2;
(II)制备FA-P(OEGMA)m-b-P(MGMA)n:在室温(25℃)通氩(Ar,2-10Pa)条件下P(OEGMA)m-b-P(MGMA)n与FA-NH2溶于含TEA的DMSO溶液中,避光反应48h后,在乙醚中沉淀,真空干燥后以氘代-二甲亚砜(DMSO-d6)为溶剂所测的氢谱结果如图3(A)所示, 6.63~8.60ppm 叶酸特征峰的出现表明聚合物FA-P(OEGMA)m-b-P(MGMA)n成功合成;
(III)制备FA-P(OEGMA)m-b-PDOX:常温(25℃)通氩 (Ar,2-10Pa)条件下,二嵌段共聚物FA-P(OEGMA)m-b-P(MGMA)n,与N2H4·H2O溶于DMF与甲醇形成的混合液中,避光反应12h,透析24h后冷冻干燥48h得到含酰肼的两亲物;将该物质与DOX·HCl在氩气 (Ar,2-10Pa)条件下溶于含等体积甲醇与DMF的混合液中,加入1滴TFA,避光室温(25℃)反应48h,透析浓缩后,以氘代二甲基亚砜(DMSO-d6)为溶剂所测的氢谱结果如图3(B)所示, 7.98~7.78 ppm阿霉素特征峰的出现表明聚合前药FA-P(OEGMA)m-b-PDOX (FA-OM@DOX)成功合成,通过核磁结果计算药载量高达61.5%;
(IV)制备聚合前药FA-OM@DOX纳米胶束: 5mg聚合前药FA-OM@DOX溶于含TEA 的DMF混合液中,搅拌0.5h后,缓慢滴加至二次水中并搅拌0.5h,在水中透析24h除去有机溶剂,即得到纳米胶束水溶液;通过比较体外毒性图6(C)与图6(D),显然FA-OM@DOX胶束作用时间相同时,口腔表皮样癌细胞(KB)的存活率低于(~4%)肺癌细胞(A549) ,表明FA-OM@DOX胶束具有靶向性。
最后说明的是,以上优选实施例仅用以说明本发明的技术方案而非限制,尽管通过上述优选实施例已经对本发明进行了详细的描述,但本领域技术人员应当理解,可以在形式上和细节上对其做出各种各样的改变,而不偏离本发明权利要求书所限定的范围。
Claims (8)
1.一种pH刺激响应性的线形二嵌段聚合前药的制备方法,其特征在于:包含以下步骤:
(1) 亲水单体P(OEGMA)m的制备,其反应式如下所示,包含以下步骤:在氩气(Ar,2-10Pa)条件下,以CPPA-NHS为RAFT反应的大分子引发剂,与乙二醇甲基丙烯酸酯(OEGMA)一并溶于1,4-二氧六环(Dio)中,加入偶氮异丁二腈(AIBN)后,冷冻-解冻循环三次,在70℃下避光反应24h,用液氮冷冻以终止反应,解冻,加3~5mL甲醇稀释,用截留分子量(MWCO)为3500Da的透析袋在甲醇中透析24 h,浓缩后得到亲水单体P(OEGMA)m,其中m表示OEGMA的聚合度聚合度(DP),它的范围为5~120;
(2) 两亲性单体P(OEGMA)m-b-P(MGMA)n的制备,包含以下步骤:
a) MGMA的制备,其反应式如下所示,包含以下步骤:在冰浴(温度≤0℃)和氩气(Ar,2-10Pa)条件下,羟基乙酸甲酯(MG)溶于含三乙胺(TEA)的二氯甲烷(DCM)溶液中并搅拌0.5h,然后将甲基丙烯酰氯(MA)溶于二氯甲烷(DCM)所形成的混合液缓慢加入,0.5h后置于室温下避光反应12h,过滤除杂,用旋转蒸发仪浓缩溶剂,进一步以乙酸乙酯、正己烷为洗脱剂过硅胶柱除去二取代产物,用旋转蒸发仪浓缩所收集溶液即得纯的甘氨酸乙酯甲基丙烯酰胺(MGMA);
b) P(OEGMA)m-b-P(MGMA)n的制备,其反应式如下所示,包含以下步骤:在氩气(Ar,2-10Pa)条件下,将步骤(1)制备的P(OEGMA)m 作为RAFT反应的大分子引发剂,与步骤(2)a)制备的MGMA一起溶于Dio中,加入AIBN后,冷冻-解冻循环三次,在70℃下避光反应24h,用液氮冷冻以终止反应,解冻,加3~5mL甲醇稀释,用MWCO为3500Da的透析袋在甲醇中透析24 h,浓缩后得到两亲性二嵌段聚合物P(OEGMA)m-b-P(MGMA)n,其中n表示MGMA的聚合度(DP),n的范围为10~120;
(3) 聚合前药P(OEGMA)m-b-PDOX的制备,其反应式如下所示,包含以下步骤:常温(25℃)通氩 (Ar,2-10Pa)条件下,将步骤(2)制备的二嵌段聚合单体P(OEGMA)m-b-P(MGMA)n与单水合肼(N2H4·H2O)溶于N,N-二甲基甲酰胺(DMF)与甲醇形成的混合液中,避光反应12h,用MWCO为3500Da的透析袋在水中透析24h后冷冻干燥48h得到含酰肼的两亲物P(OEGMA)m-b-hydrazide,将该物质与盐酸阿霉素(DOX·HCl)在氩气 (Ar,2-10Pa)条件下溶于含等体积甲醇与DMF的混合液中,加入1滴三氟乙酸(TFA)后避光室温(25℃)反应48h,用MWCO为3500Da的透析袋在甲醇中透析,用旋转蒸发仪浓缩后即得到聚合前药P(OEGMA)m-b-PDOX(简称为OM@DOX);
(4) pH刺激响应性聚合前药OM@DOX纳米胶束的制备,包含以下步骤:取步骤(3)制备的聚合物前药OM@DOX,将OM@DOX溶于含TEA的DMF混合液中,搅拌0.5h后,缓慢滴加至二次水中并搅拌0.5h,用MWCO为3500Da的透析袋在水中透析24h除去有机溶剂,即得到OM@DOX纳米胶束水溶液。
2.一种pH刺激响应性的线形二嵌段聚合前药的制备方法,其特征在于该聚合前药还具有靶向性:包含以下步骤:
(I) FA-NH2的制备,其反应式如下所示,包含以下步骤:在冰浴(温度≤0℃)和氩气(Ar,2-10Pa)条件下,将具有靶向性的叶酸(FA)溶于无水的DMF中,加入催化剂1-(3-二甲氨基丙基)-3-乙基碳二亚胺 (EDC)和N-羟基硫代琥珀酰亚胺(NHS),搅拌0.5h后,加入N-叔丁氧羰基-1,6-己二胺(NH2-BOC)溶于含TEA的DMF的混合液,在室温下(25℃)反应24h,缓慢滴加至不断搅拌的二次水中,过滤,真空干燥后得到氨基被叔丁氧羰基保护的FA-NH-BOC,加入DCM和TFA溶剂并搅拌0.5h,浓缩,加入DCM及TEA,避光室温(25℃)搅拌24h,转速设为5000r/min离心3min,用DCM洗两次,真空干燥后得到FA-NH2;
(II) FA-P(OEGMA)m-b-P(MGMA)n的制备,其反应式如下所示,包含以下步骤:在室温(25℃)通氩(Ar,2-10Pa)条件下将权利要求1中步骤(2)制备的二嵌段聚合物P(OEGMA)m-b-P(MGMA)n与步骤(I)制备的FA-NH2溶于含TEA的无水二甲亚砜(DMSO)溶液中,避光反应48h后,缓慢滴加至乙醚中沉淀,真空干燥得到接叶酸的两亲性聚合物FA-P(OEGMA)m-b-P(MGMA)n;
(III) 聚合前药FA-P(OEGMA)m-b-PDOX的制备,其反应式如下所示,包含以下步骤:常温(25℃)通氩 (Ar,2-10Pa)条件下,将步骤(II)中制备的二嵌段共聚物FA-P(OEGMA)m-b-P(MGMA)n与单水合肼(N2H4·H2O)溶于N,N-二甲基甲酰胺(DMF)与甲醇形成的混合液中,避光反应12h,用MWCO为3500Da的透析袋在水中透析24h后冷冻干燥48h得到含酰肼的两亲物FA-P(OEGMA)m-b-hydrazide,将该物质与DOX·HCl在氩气 (Ar,2-10Pa)条件下溶于含等体积甲醇与DMF的混合液中,加入1滴三氟乙酸(TFA)后避光室温(25℃)反应48h,用MWCO为3500Da的透析袋在甲醇中透析,用旋转蒸发仪浓缩后即得到聚合前药FA-P(OEGMA)m-b-PDOX,记为FA-OM@DOX;
(IV) pH刺激响应性聚合前药FA-OM@DOX纳米胶束的制备,包含以下步骤:取步骤(III)制备的聚合前药FA-OM@DOX,将FA-OM@DOX溶于含TEA的DMF混合液中,搅拌0.5h后,缓慢滴加至二次水中并搅拌0.5h,用MWCO为3500Da的透析袋在水中透析24h除去有机溶剂,即得到FA-OM@DOX的纳米胶束水溶液。
3.根据权利要求1所述的一种pH刺激响应性的线形二嵌段聚合前药的制备方法,其特征在于:所述步骤(1)中AIBN、CPPA-NHS和OEGMA的摩尔浓度比为1:(2.4~6.7) :(8~24)。
4.根据权利要求1所述的一种pH刺激响应性的线形二嵌段聚合前药的制备方法,其特征在于:所述步骤(2)a)中TEA与DCM的体积比范围为1:(2~4.5);所述步骤(2)a)中MG和MA的摩尔浓度范围比为1:(1.7~2.3) ;所述步骤(2)a)中乙酸乙酯和正己烷的体积比为1:(3.62~4.8); 所述步骤(2)b)中P(OEGMA)m 和MGMA摩尔浓度比为1:(10~80)。
5.根据权利要求1所述的一种pH刺激响应性的线形二嵌段聚合前药的制备方法,其特征在于:所述步骤(3)中 P(OEGMA)m-b-P(MGMA)n、P(OEGMA)m-b-hydrazide和DOX·HCl的摩尔浓度比为1:(1.2~3.6):(1.4~5.1);所述步骤(3)中N2H4·H2O、甲醇、DMF和TFA的体积比为1:(6~10):(2~7):(0.1~0.4)。
6.根据权利要求2所述的一种pH刺激响应性的线形二嵌段聚合前药的制备方法,其特征在于:所述步骤(I)中FA、EDC、NHS、NH2-BOC和TEA的摩尔浓度比范围为1:(1.01~1.2):(1.04~1.3):(1.8~2.4) (1.4~2.2);所述步骤(I) 中DCM、TFA和TEA的体积比范围为1:(0.92~1.08):(1.8~2.4);所述步骤(II) 中P(OEGMA)m-b-P(MGMA)n、FA-NH2和TEA的摩尔浓度比范围为1:(1.01~1.2) :(1.01~1.2);所述步骤(III)中FA-P(OEGMA)m-b-P(MGMA)n、FA-P(OEGMA)m-b-hydrazide和DOX·HCl的摩尔浓度比范围为1:(1.2~3.6):(1.4~5.1);所述步骤(III)中N2H4·H2O、甲醇、DMF和TFA的体积比范围为1:(6~10):(2~7):(0.1~0.4)。
7.根据权利要求1和2所述的一种pH刺激响应性的线形二嵌段聚合前药的制备方法,其特征在于:所述步骤(4)和步骤(IV)中聚合前药中阿霉素的浓度范围为0.01mg·L-1~0.05mg·L-1;所述步骤(4)和步骤(IV)中DMF和水的体积比范围为1:(6~500);所述步骤(4)和步骤(IV)中透析后所得的纳米胶束粒径范围为10~1000nm。
8.根据权利要求1-7任一项所述方法制备pH刺激响应性的线形二嵌段聚合前药。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710477273.9A CN107236100B (zh) | 2017-06-21 | 2017-06-21 | 一种pH刺激响应性的线形二嵌段聚合前药的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710477273.9A CN107236100B (zh) | 2017-06-21 | 2017-06-21 | 一种pH刺激响应性的线形二嵌段聚合前药的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107236100A true CN107236100A (zh) | 2017-10-10 |
CN107236100B CN107236100B (zh) | 2019-03-29 |
Family
ID=59987172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710477273.9A Expired - Fee Related CN107236100B (zh) | 2017-06-21 | 2017-06-21 | 一种pH刺激响应性的线形二嵌段聚合前药的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107236100B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108864385A (zh) * | 2018-05-29 | 2018-11-23 | 上海交通大学 | 一种含精准修饰位点聚合物刷的制备方法 |
CN112353948A (zh) * | 2020-10-21 | 2021-02-12 | 四川大学 | 响应酸性微环境实现粒径减小和表面电荷翻转的载药胶束及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101259284A (zh) * | 2008-04-15 | 2008-09-10 | 华东师范大学 | 一种基于树形聚合物肝靶向抗癌纳米前药系统、制备及用途 |
CN105168230A (zh) * | 2015-09-02 | 2015-12-23 | 上海市普陀区中心医院 | 一种具有内涵体逃逸功能的肿瘤靶向前药及其纳米制剂和制备方法 |
CN105169404A (zh) * | 2015-09-02 | 2015-12-23 | 上海市普陀区中心医院 | 一种用于治疗去势抵抗性前列腺癌的靶向前药及其纳米制剂和制备方法 |
-
2017
- 2017-06-21 CN CN201710477273.9A patent/CN107236100B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101259284A (zh) * | 2008-04-15 | 2008-09-10 | 华东师范大学 | 一种基于树形聚合物肝靶向抗癌纳米前药系统、制备及用途 |
CN105168230A (zh) * | 2015-09-02 | 2015-12-23 | 上海市普陀区中心医院 | 一种具有内涵体逃逸功能的肿瘤靶向前药及其纳米制剂和制备方法 |
CN105169404A (zh) * | 2015-09-02 | 2015-12-23 | 上海市普陀区中心医院 | 一种用于治疗去势抵抗性前列腺癌的靶向前药及其纳米制剂和制备方法 |
Non-Patent Citations (3)
Title |
---|
SON H.N.等: "Chemotherapeutic copolymers prepared via the RAFT polymerization of prodrug monomers", 《POLYMER CHEMISTRY》 * |
WANG HAIBO等: "Bioinspired phospholipid polymer prodrug as a pH-responsive drug delivery system for cancer therapy", 《POLYMER CHEMISTRY》 * |
XU ZHIGANG等: "A novel nanoassembled doxorubicin prodrug with a high drug loading for anticancer drug delivery", 《JOURNAL OF MATERIALS CHEMISTRY B》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108864385A (zh) * | 2018-05-29 | 2018-11-23 | 上海交通大学 | 一种含精准修饰位点聚合物刷的制备方法 |
CN112353948A (zh) * | 2020-10-21 | 2021-02-12 | 四川大学 | 响应酸性微环境实现粒径减小和表面电荷翻转的载药胶束及其制备方法 |
CN112353948B (zh) * | 2020-10-21 | 2021-08-27 | 四川大学 | 响应酸性微环境实现粒径减小和表面电荷翻转的载药胶束及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107236100B (zh) | 2019-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102633959B (zh) | 一种具有pH响应性的梳状共聚物及其制法和应用 | |
CN106963733A (zh) | 一类两亲性星形阿霉素聚合物前药的制备方法 | |
CN107596383B (zh) | 一类pH响应的两亲性棒状阿霉素聚合物前药的制备方法 | |
CN103656652B (zh) | 一种双敏感响应型聚合物纳米胶束及其制备方法和应用 | |
Jiang et al. | A tumor-targeting nano doxorubicin delivery system built from amphiphilic polyrotaxane-based block copolymers | |
CN106317416A (zh) | 一种双pH响应的两亲性共聚物及其制备方法和用途 | |
CN110433294B (zh) | 基于偶氮苯的乏氧响应性胶束及其制备方法和应用 | |
CN109364262A (zh) | 一种氧化还原双响应型高分子喜树碱前药的制备方法 | |
CN103251596A (zh) | 7-乙基-10-羟基喜树碱的两亲性聚合物药物前体及其制备方法和纳米颗粒 | |
CN105175656A (zh) | 一种温度和氧化剂双重刺激响应性纳米聚集体制备方法和应用 | |
CN102863627A (zh) | 顺铂配合物及其制备方法 | |
CN110483785A (zh) | 一种三嵌段聚合物、载药纳米胶束、纳米药物及其制备方法和应用 | |
CN102432783B (zh) | 一种pH响应/疏水基团无规共聚聚合物及其制法和应用 | |
CN108310395A (zh) | 一种表面电荷可转换的聚合物纳米药物载体及制备方法和应用 | |
CN104031270B (zh) | 可完全解离型聚乙二醇-聚(L-谷氨酸-γ-苄酯)-聚乙烯亚胺共聚物及其合成方法和应用 | |
CN104262600B (zh) | 同一侧基上含有西弗碱和巯基的双重敏感型两亲性共聚物及其制备方法与应用 | |
CN104027816B (zh) | 一种可去聚乙二醇化的共装载阿霉素和siRNA载体及其合成方法 | |
CN107236100A (zh) | 一种pH刺激响应性的线形二嵌段聚合前药的制备方法 | |
CN108774301A (zh) | 一类基于葡聚糖的酸响应聚合物药物的制备方法及其应用 | |
CN105820299B (zh) | 一种亲疏水端同时具有pH响应的聚合物胶束及其制备和应用 | |
CN104027813A (zh) | 一种pH/还原双重敏感的亲水性共聚物药物载体及其合成方法和应用 | |
CN110628035B (zh) | 酶和pH双重响应性共聚物及其制备方法和应用 | |
CN105168230B (zh) | 一种具有内涵体逃逸功能的肿瘤靶向前药及其纳米制剂和制备方法 | |
CN104974353B (zh) | 基于聚β胺基酯的pH响应三嵌段线性聚合物及胶束系统 | |
CN104524584B (zh) | 一种逐级响应的纳米载体、其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190329 |